A lipoprotein receptor cluster IV mutant preferentially binds amyloid-β and regulates its clearance from the mouse brain

Journal of Biological Chemistry

Volumn 288, Issue 21, 2013, Pages 15154-15166

  Sagare, Abhay P ^a   Bell, Robert D ^b   Srivastava, Alaka ^c   Sengillo, Jesse D ^a   Singh, Itender ^b   Nishida, Yoichiro ^b   Chow, Nienwen ^c   Zlokovic, Berislav V ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c ZZ Alztech   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID RESIDUES; EXPERIMENTAL STUDIES; HIPPOCAMPAL FUNCTIONS; LIPOPROTEIN RECEPTORS; LOW DENSITY LIPOPROTEINS; MATRIX METALLOPROTEINASE-9; MILD COGNITIVE IMPAIRMENTS; TISSUE PLASMINOGEN ACTIVATOR;

AMINO ACIDS; BINDING ENERGY; BRAIN; CEREBROSPINAL FLUID; GLYCOPROTEINS; LIGANDS; LIPOPROTEINS; TISSUE;

MAMMALS;

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; ASPARTIC ACID; BLOOD CLOTTING FACTOR 10A; GELATINASE B; GLYCINE; LIPOPROTEIN RECEPTOR; LIPOPROTEIN RECEPTOR CLUSTER IV; MUTANT PROTEIN; PROTEIN VARIANT; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BRAIN BLOOD FLOW; BRAIN CORTEX; BRAIN FUNCTION; CALCIUM BINDING; CEREBROSPINAL FLUID; CONTROLLED STUDY; FEMALE; HIPPOCAMPUS; IN VITRO STUDY; LIGAND BINDING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RECEPTOR AFFINITY;

AGING; ALZHEIMER DISEASE; AMYLOID; AMYLOID PRECURSOR PROTEIN; AMYLOID-BETA; CLEARANCE THERAPY; LIPOPROTEIN RECEPTOR; LRPIV MUTANT; NEURODEGENERATIVE DISEASES; SLRP1;

ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; AMYLOID BETA-PEPTIDES; ANIMALS; CEREBRAL CORTEX; CEREBROVASCULAR CIRCULATION; CHO CELLS; CRICETINAE; CRICETULUS; HIPPOCAMPUS; HUMANS; LIGANDS; MICE; MICE, MUTANT STRAINS; MUTATION, MISSENSE; PEPTIDE FRAGMENTS; PROTEIN BINDING; RECEPTORS, LDL; TUMOR SUPPRESSOR PROTEINS;

EID: 84878260940     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.439570     Document Type: Article

References (71)

1. Querfurth, H. W., and LaFerla, F. M. (2010) Alzheimer's disease. N. Engl. J. Med. 362, 329-344
2. Selkoe, D. J. (2001) Alzheimer's disease. Genes, proteins, and therapy. Physiol. Rev. 81, 741-766
3. Benilova, I., Karran, E., and De Strooper, B. (2012) The toxic Aβ oligomer and Alzheimer's disease. An emperor in need of clothes. Nat. Neurosci. 15, 349-357
4. Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., Zhu, H., Ghiso, J., Frangione, B., Stern, A., Schmidt, A. M., Armstrong, D. L., Arnold, B., Liliensiek, B., Nawroth, P., Hofman, F., Kindy, M., Stern, D., and Zlokovic, B. (2003) RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 9, 907-913 (Pubitemid 36889934)
5. Zlokovic, B. V., Deane, R., Sagare, A. P., Bell, R. D., and Winkler, E. A. (2010) Low-density lipoprotein receptor-related protein-1. A serial clearance homeostatic mechanism controlling Alzheimer's amyloid β-peptide elimination from the brain. J. Neurochem. 115, 1077-1089
6. Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., and Bateman, R. J. (2010) Decreased clearance of CNS β-amyloid in Alzheimer's disease. Science 330, 1774
7. Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., and Zlokovic, B. V. (2000) Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106, 1489-1499 (Pubitemid 32038587)
8. Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., Xu, F., Parisi, M., LaRue, B., Hu, H. W., Spijkers, P., Guo, H., Song, X., Lenting, P. J., Van Nostrand, W. E., and Zlokovic, B. V. (2004) LRP/amyloid β-peptide interaction mediates differential brain efflux of Aβ isoforms. Neuron 43, 333-344 (Pubitemid 39061126)
9. Ito, S., Ohtsuki, S., and Terasaki, T. (2006) Functional characterization of the brain-to-blood efflux clearance of human amyloid-β peptide (1-40) across the rat blood-brain barrier. Neurosci. Res. 56, 246-252 (Pubitemid 44572534)
10. Saido, T., and Leissring, M. A. (2012) Proteolytic degradation of amyloid β-protein. Cold Spring Harb. Perspect. Med. 2, a006379
11. Zlokovic, B. V. (2011) Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat. Rev. Neurosci. 12, 723-738
12. Banks, W. A., Robinson, S. M., Verma, S., and Morley, J. E. (2003) Efflux of human and mouse amyloid β proteins 1-40 and 1-42 from brain. Impairment in a mouse model of Alzheimer's disease. Neuroscience 121, 487-492 (Pubitemid 37176936)
13. Bell, R. D., Sagare, A. P., Friedman, A. E., Bedi, G. S., Holtzman, D. M., Deane, R., and Zlokovic, B. V. (2007) Transport pathways for clearance of human Alzheimer's amyloid β-peptide and apolipoproteins E and J in the mouse central nervous system. J. Cereb. Blood Flow Metab. 27, 909-918 (Pubitemid 46659038)
14. Sagare, A., Deane, R., Bell, R. D., Johnson, B., Hamm, K., Pendu, R., Marky, A., Lenting, P. J., Wu, Z., Zarcone, T., Goate, A., Mayo, K., Perlmutter, D., Coma, M., Zhong, Z., and Zlokovic, B. V. (2007) Clearance of amyloid-β by circulating lipoprotein receptors. Nat. Med. 13, 1029-1031 (Pubitemid 47517512)
15. Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., and Zlokovic, B. V. (2008) apoE isoform-specific disruption of amyloid β peptide clearance from mouse brain. J. Clin. Invest. 118, 4002-4013
16. Jaeger, L. B., Dohgu, S., Hwang, M. C., Farr, S. A., Murphy, M. P., Fleegal-DeMotta, M. A., Lynch, J. L., Robinson, S. M., Niehoff, M. L., Johnson, S. N., Kumar, V. B., and Banks, W. A. (2009) Testing the neurovascular hypothesis of Alzheimer's disease. LRP-1 antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-β protein, and impairs cognition. J. Alzheimers Dis. 17, 553-570
17. Bell, R. D., Deane, R., Chow, N., Long, X., Sagare, A., Singh, I., Streb, J. W., Guo, H., Rubio, A., Van Nostrand, W., Miano, J. M., and Zlokovic, B. V. (2009) SRF and myocardin regulate LRP-mediated amyloid-β clearance in brain vascular cells. Nat. Cell Biol. 11, 143-153
18. Sehgal, N., Gupta, A., Valli, R. K., Joshi, S. D., Mills, J. T., Hamel, E., Khanna, P., Jain, S. C., Thakur, S. S., and Ravindranath, V. (2012) Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc. Natl. Acad. Sci. U.S.A. 109, 3510-3515
19. Sagare, A. P., Deane, R., and Zlokovic, B. V. (2012) Low-density lipoprotein receptor-related protein 1. A physiological Aβ homeostatic mechanism with multiple therapeutic opportunities. Pharmacol. Ther. 136, 94-105
20. Qosa, H., Abuznait, A. H., Hill, R. A., and Kaddoumi, A. (2012) Enhanced brain amyloid-β clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease. J. Alzheimers Dis. 31, 151-165
21. Kanekiyo, T., Liu, C. C., Shinohara, M., Li, J., and Bu, G. (2012) LRP1 in brain vascular smooth muscle cells mediates local clearance of Alzheimer's amyloid-β. J. Neurosci. 32, 16458-16465
22. Sagare, A. P., Deane, R., Zetterberg, H., Wallin, A., Blennow, K., and Zlokovic, B. V. (2011) Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-β is an early biomarker for mild cognitive impairment preceding Alzheimer's disease. J. Alzheimers Dis. 24, 25-34
23. Ujiie, M., Dickstein, D. L., Carlow, D. A., and Jefferies, W. A. (2003) Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation 10, 463-470 (Pubitemid 39004272)
24. Donahue, J. E., Flaherty, S. L., Johanson, C. E., Duncan, J. A., 3rd, Silverberg, G. D., Miller, M. C., Tavares, R., Yang, W., Wu, Q., Sabo, E., Hovanesian, V., and Stopa, E. G. (2006) RAGE, LRP-1, and amyloid-β protein in Alzheimer's disease. Acta Neuropathol. 112, 405-415 (Pubitemid 44469161)
25. DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J. C., Paul, S. M., and Holtzman, D. M. (2001) Peripheral anti-A β antibody alters CNS and plasma A β clearance and decreases brain A β burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 98, 8850-8855 (Pubitemid 32678116)
26. Herrmann, N., Chau, S. A., Kircanski, I., and Lanctôt, K. L. (2011) Current and emerging drug treatment options for Alzheimer's disease. A systematic review. Drugs 71, 2031-2065
27. Pfeifer, M., Boncristiano, S., Bondolfi, L., Stalder, A., Deller, T., Staufenbiel, M., Mathews, P. M., and Jucker, M. (2002) Cerebral hemorrhage after passive anti-Aβ immunotherapy. Science 298, 1379 (Pubitemid 35346131)
28. Wilcock, D. M., Morgan, D., Gordon, M. N., Taylor, T. L., Ridnour, L. A., Wink, D. A., and Colton, C. A. (2011) Activation of matrix metalloproteinases following anti-Aβ immunotherapy. Implications for microhemorrhage occurrence. J. Neuroinflammation 8, 115
29. Kou, J., Kim, H., Pattanayak, A., Song, M., Lim, J. E., Taguchi, H., Paul, S., Cirrito, J. R., Ponnazhagan, S., and Fukuchi, K. (2011) Anti-amyloid-β single-chain antibody brain delivery via AAV reduces amyloid load but may increase cerebral hemorrhages in an Alzheimer's disease mouse model. J. Alzheimers Dis. 27, 23-38
30. Selkoe, D. J. (2012) Preventing Alzheimer's disease. Science 337, 1488-1492
31. Klaver, A. C., Finke, J. M., Digambaranath, J., Balasubramaniam, M., and Loeffler, D. A. (2010) Antibody concentrations to Aβ1-42 monomer and soluble oligomers in untreated and antibody-antigen-dissociated intravenous immunoglobulin preparations. Int. Immunopharmacol. 10, 115-119
32. Dodel, R., Neff, F., Noelker, C., Pul, R., Du, Y., Bacher, M., and Oertel, W. (2010) Intravenous immunoglobulins as a treatment for Alzheimer's disease. Rationale and current evidence. Drugs 70, 513-528
33. Blacklow, S. C., and Kim, P. S. (1996) Protein folding and calcium binding defects arising from familial hypercholesterolemia mutations of the LDL receptor. Nat. Struct. Biol. 3, 758-762 (Pubitemid 26303401)
34. Atkins, A. R., Brereton, I. M., Kroon, P. A., Lee, H. T., and Smith, R. (1998) Calcium is essential for the structural integrity of the cysteine-rich, ligand-binding repeat of the low-density lipoprotein receptor. Biochemistry 37, 1662-1670 (Pubitemid 28093682)
35. Meijer, A. B., Rohlena, J., van der Zwaan, C., van Zonneveld, A. J., Boertjes, R. C., Lenting, P. J., and Mertens, K. (2007) Functional duplication of ligand-binding domains within low-density lipoprotein receptor-related protein for interaction with receptor associated protein, α2- macroglobulin, factor IXa and factor VIII. Biochim. Biophys. Acta 1774, 714-722 (Pubitemid 46856288)
36. Obermoeller, L. M., Warshawsky, I., Wardell, M. R., and Bu, G. (1997) Differential functions of triplicated repeats suggest two independent roles for the receptor-associated protein as a molecular chaperone. J. Biol. Chem. 272, 10761-10768 (Pubitemid 27181089)
37. Croy, J. E., Shin, W. D., Knauer, M. F., Knauer, D. J., and Komives, E. A. (2003) All three LDL receptor homology regions of the LDL receptor-related protein bind multiple ligands. Biochemistry 42, 13049-13057 (Pubitemid 37385837)
38. Neels, J. G., van Den Berg, B. M., Lookene, A., Olivecrona, G., Pannekoek, H., and van Zonneveld, A. J. (1999) The second and fourth cluster of class A cysteine-rich repeats of the low density lipoprotein receptor-related protein share ligand-binding properties. J. Biol. Chem. 274, 31305-31311
39. Herz, J., Goldstein, J. L., Strickland, D. K., Ho, Y. K., and Brown, M. S. (1991) 39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/α2-macroglobulin receptor. J. Biol. Chem. 266, 21232-21238 (Pubitemid 21908599)
40. Deane, R., Bell, R. D., Sagare, A., and Zlokovic, B. V. (2009) Clearance of amyloid-β peptide across the blood-brain barrier. Implication for therapies in Alzheimer's disease. CNS Neurol. Disord. Drug Targets 8, 16-30
41. Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., and Glabe, C. G. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489 (Pubitemid 36444329)
42. Kayed, R., Head, E., Sarsoza, F., Saing, T., Cotman, C. W., Necula, M., Margol, L., Wu, J., Breydo, L., Thompson, J. L., Rasool, S., Gurlo, T., Butler, P., and Glabe, C. G. (2007) Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol. Neurodegener. 2, 18
43. Mackic, J. B., Weiss, M. H., Miao, W., Kirkman, E., Ghiso, J., Calero, M., Bading, J., Frangione, B., and Zlokovic, B. V. (1998) Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer's amyloid β peptide in aged squirrel monkey with cerebral amyloid angiopathy. J. Neurochem. 70, 210-215 (Pubitemid 28020845)
44. Deane, R., Sagare, A., Hamm, K., Parisi, M., LaRue, B., Guo, H., Wu, Z., Holtzman, D. M., and Zlokovic, B. V. (2005) IgG-assisted age-dependent clearance of Alzheimer's amyloid β peptide by the blood-brain barrier neonatal Fc receptor. J. Neurosci. 25, 11495-11503 (Pubitemid 43102486)
45. Wahrle, S. E., Jiang, H., Parsadanian, M., Legleiter, J., Han, X., Fryer, J. D., Kowalewski, T., and Holtzman, D. M. (2004) ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J. Biol. Chem. 279, 40987-40993 (Pubitemid 39287699)
46. Deacon, R. M. (2009) Burrowing. A sensitive behavioural assay, tested in five species of laboratory rodents. Behav. Brain Res. 200, 128-133
47. Deane, R., Singh, I., Sagare, A. P., Bell, R. D., Ross, N. T., LaRue, B., Love, R., Perry, S., Paquette, N., Deane, R. J., Thiyagarajan, M., Zarcone, T., Fritz, G., Friedman, A. E., Miller, B. L., and Zlokovic, B. V. (2012) A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. J. Clin. Invest. 122, 1377-1392
48. Zhong, Z., Deane, R., Ali, Z., Parisi, M., Shapovalov, Y., O'Banion, M. K., Stojanovic, K., Sagare, A., Boillee, S., Cleveland, D. W., and Zlokovic, B. V. (2008) ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat. Neurosci. 11, 420-422 (Pubitemid 351441888)
49. Horn, I. R., van den Berg, B. M., van der Meijden, P. Z., Pannekoek, H., and van Zonneveld, A. J. (1997) Molecular analysis of ligand binding to the second cluster of complement-type repeats of the low density lipoprotein receptor-related protein. Evidence for an allosteric component in receptor-associated protein-mediated inhibition of ligand binding. J. Biol. Chem. 272, 13608-13613 (Pubitemid 27224792)
50. Westein, E., Denis, C. V., Bouma, B. N., and Lenting, P. J. (2002) The α-chains of C4b-binding protein mediate complex formation with low density lipoprotein receptor-related protein. J. Biol. Chem. 277, 2511-2516 (Pubitemid 34953274)
51. Leyte, A., Mertens, K., Distel, B., Evers, R. F., De Keyzer-Nellen, M. J., Groenen-Van Dooren, M. M., De Bruin, J., Pannekoek, H., Van Mourik, J. A., and Verbeet, M. P. (1989) Inhibition of human coagulation factor VIII by monoclonal antibodies. Biochem. J. 263, 187-194
52. Mackic, J. B., Bading, J., Ghiso, J., Walker, L., Wisniewski, T., Frangione, B., and Zlokovic, B. V. (2002) Circulating amyloid-β peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. Vascul. Pharmacol. 38, 303-313 (Pubitemid 36398252)
53. Dodel, R., Hampel, H., Depboylu, C., Lin, S., Gao, F., Schock, S., Jäckel, S., Wei, X., Buerger, K., Höft, C., Hemmer, B., Möller, H. J., Farlow, M., Oertel, W. H., Sommer, N., and Du, Y. (2002) Human antibodies against amyloid β peptide. A potential treatment for Alzheimer's disease. Ann. Neurol. 52, 253-256 (Pubitemid 34810613)
54. Szabo, P., Mujalli, D. M., Rotondi, M. L., Sharma, R., Weber, A., Schwarz, H. P., Weksler, M. E., and Relkin, N. (2010) Measurement of anti-β amyloid antibodies in human blood. J. Neuroimmunol. 227, 167-174
55. Balakrishnan, K., Andrei-Selmer, L. C., Selmer, T., Bacher, M., and Dodel, R. (2010) Comparison of intravenous immunoglobulins for naturally occurring autoantibodies against amyloid-β. J. Alzheimers Dis. 20, 135-143
56. Bach, J. P., and Dodel, R. (2012) Naturally occurring autoantibodies against β-amyloid. Adv. Exp. Med. Biol. 750, 91-99
57. Du, Y., Dodel, R., Hampel, H., Buerger, K., Lin, S., Eastwood, B., Bales, K., Gao, F., Moeller, H. J., Oertel, W., Farlow, M., and Paul, S. (2001) Reduced levels of amyloid β-peptide antibody in Alzheimer disease. Neurology 57, 801-805 (Pubitemid 32845498)
58. Britschgi, M., Olin, C. E., Johns, H. T., Takeda-Uchimura, Y., LeMieux, M. C., Rufibach, K., Rajadas, J., Zhang, H., Tomooka, B., Robinson, W. H., Clark, C. M., Fagan, A. M., Galasko, D. R., Holtzman, D. M., Jutel, M., Kaye, J. A., Lemere, C. A., Leszek, J., Li, G., Peskind, E. R., Quinn, J. F., Yesavage, J. A., Ghiso, J. A., and Wyss-Coray, T. (2009) Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 106, 12145-12150
59. DeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M., and Holtzman, D. M. (2002) Brain to plasma amyloid-β efflux. A measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295, 2264-2267 (Pubitemid 34258840)
60. Relkin, N. R., Szabo, P., Adamiak, B., Burgut, T., Monthe, C., Lent, R. W., Younkin, S., Younkin, L., Schiff, R., and Weksler, M. E. (2009) 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging 30, 1728-1736
61. Shayan, G., Adamiak, B., Relkin, N. R., and Lee, K. H. (2012) Longitudinal analysis of novel Alzheimer's disease proteomic cerebrospinal fluid biomarkers during intravenous immunoglobulin therapy. Electrophoresis 33, 1975-1979
62. Matsuoka, Y., Saito, M., LaFrancois, J., Saito, M., Gaynor, K., Olm, V., Wang, L., Casey, E., Lu, Y., Shiratori, C., Lemere, C., and Duff, K. (2003) Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to β-amyloid. J. Neurosci. 23, 29-33 (Pubitemid 36050401)
63. Hirko, A. C., Meyer, E. M., King, M. A., and Hughes, J. A. (2007) Peripheral transgene expression of plasma gelsolin reduces amyloid in transgenic mouse models of Alzheimer's disease. Mol. Ther. 15, 1623-1629 (Pubitemid 47289005)
64. Wu, Z., Guo, H., Chow, N., Sallstrom, J., Bell, R. D., Deane, R., Brooks, A. I., Kanagala, S., Rubio, A., Sagare, A., Liu, D., Li, F., Armstrong, D., Gasiewicz, T., Zidovetzki, R., Song, X., Hofman, F., and Zlokovic, B. V. (2005) Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nat. Med. 11, 959-965 (Pubitemid 41294441)
65. Tamaki, C., Ohtsuki, S., Iwatsubo, T., Hashimoto, T., Yamada, K., Yabuki, C., and Terasaki, T. (2006) Major involvement of low-density lipoprotein receptor-related protein 1 in the clearance of plasma free amyloid β-peptide by the liver. Pharm. Res. 23, 1407-1416 (Pubitemid 43993806)
66. Zloković, B. V., Lipovac, M. N., Begley, D. J., Davson, H., and Rakić, L. (1987) Transport of leucine-enkephalin across the blood-brain barrier in the perfused guinea pig brain. J. Neurochem. 49, 310-315
67. Andersen, O. M., Christensen, P. A., Christensen, L. L., Jacobsen, C., Moestrup, S. K., Etzerodt, M., and Thogersen, H. C. (2000) Specific binding of α-macroglobulin to complement-type repeat CR4 of the low-density lipoprotein receptor-related protein. Biochemistry 39, 10627-10633
68. Andersen, O. M., Reiche, J., Schmidt, V., Gotthardt, M., Spoelgen, R., Behlke, J., von Arnim, C. A., Breiderhoff, T., Jansen, P., Wu, X., Bales, K. R., Cappai, R., Masters, C. L., Gliemann, J., Mufson, E. J., Hyman, B. T., Paul, S. M., Nykjaer, A., and Willnow, T. E. (2005) Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc. Natl. Acad. Sci. U.S.A. 102, 13461-13466 (Pubitemid 41420870)
69. Gregory, J. L., Prada, C. M., Fine, S. J., Garcia-Alloza, M., Betensky, R. A., Arbel-Ornath, M., Greenberg, S. M., Bacskai, B. J., and Frosch, M. P. (2012) Reducing available soluble β-amyloid prevents progression of cerebral amyloid angiopathy in transgenic mice. J. Neuropathol. Exp. Neurol. 71, 1009-1017
70. Huang, Y., and Mucke, L. (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204-1222
71. Galluzzi, S., Geroldi, C., Amicucci, G., Bocchio-Chiavetto, L., Bonetti, M., Bonvicini, C., Cotelli, M., Ghidoni, R., Paghera, B., Zanetti, O., and Frisoni, G. B. (2013) Supporting evidence for using biomarkers in the diagnosis of MCI due to AD. J. Neurol. 260, 640-650